Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 8/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 6/20 | 0.41 |
| ▸ | TESK1 | Q15569 | 3/20 | 0.41 |
| ▸ | TESK2 | Q96S53 | 3/20 | 0.41 |
| ▸ | LCK | P06239 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | LATS1 | O95835 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903828 | 0.83 | KDR (0.40) | LIMK1LIMK2TESK1TESK2CSNK2A2 | |
| SCHEMBL17580713 | 0.81 | LIMK1 (0.40) | LIMK1LIMK2TESK1TESK2LCK | |
| SCHEMBL28518148 | 0.80 | LIMK1 (0.51) | LIMK1LIMK2TESK1TESK2LCK | |
| SCHEMBL28247393 | 0.79 | LIMK1 (0.49) | LIMK1LCKNAMPTCSNK2A2CSNK2A1 | |
| SCHEMBL4299418 | 0.78 | CDK2 (0.46) | LIMK1LIMK2TESK1TESK2LCK | |
| SCHEMBL16513227 | 0.76 | LIMK1 (0.46) | LIMK1LIMK2TESK1TESK2LCK | |
| SCHEMBL4296569 | 0.76 | ROCK2 (0.47) | NAMPTLATS1CYP17A1 | |
| SCHEMBL31501342 | 0.75 | MKNK1 (0.60) | — | |
| SCHEMBL25602729 | 0.75 | MKNK1 (0.60) | — | |
| SCHEMBL4294343 | 0.73 | GSK3B (0.47) | LCKCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | LIMK1 1129/4885LIMK2 674/4885TESK1 1460/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | LIMK1 1141/4885LIMK2 535/4885TESK1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.